A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group.
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS128-TPS128
2013 ◽
Vol 8
(8)
◽
pp. 1091-1094
◽
2009 ◽
Vol 4
(1)
◽
pp. 97-101
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8532-8532
◽
2009 ◽
Vol 147
(4)
◽
pp. 507-514
◽
1999 ◽
Vol 57
(2)
◽
pp. 201-206
◽